Cart
sales@molnova.com
SARS-CoV-2-IN-38
CAS No. 2882823-27-8
SARS-CoV-2-IN-38( —— )
Catalog No. M37222 CAS No. 2882823-27-8
SARS-CoV-2-IN-38 is an orally available SARS-CoV-2 inhibitor with potential antiviral activity for the study of SARS viral infections.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 411 | In Stock |
|
| 10MG | 562 | In Stock |
|
| 25MG | 866 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSARS-CoV-2-IN-38
-
NoteResearch use only, not for human use.
-
Brief DescriptionSARS-CoV-2-IN-38 is an orally available SARS-CoV-2 inhibitor with potential antiviral activity for the study of SARS viral infections.
-
DescriptionSARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor with good oral bioavailability in mice (F%=39.75%).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorSARS-CoV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2882823-27-8
-
Formula Weight419.76
-
Molecular FormulaC18H14ClF4NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(OC1=CC(F)=C(Cl)C=C1C(=O)NC2=CC=C(OC(F)(F)F)C=C2)C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li R, et al. Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2. Eur J Med Chem. 2023 May 5;253:115320. ?
molnova catalog
related products
-
Malvidin-3-O-arabino...
Malvidin-3-O-arabinoside chloride has antioxidant activity.It has potential preventive effect in colorectal diseases.
-
PF-00835231
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
-
lorvotuzumab
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.
